Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Thomas Jefferson University
Roswell Park Cancer Institute
NRG Oncology
Mayo Clinic
AHS Cancer Control Alberta
University of Southern California
University of California, San Francisco
University of Washington
AHS Cancer Control Alberta
Masonic Cancer Center, University of Minnesota
University Hospitals Bristol and Weston NHS Foundation Trust
University of California, Davis